Table 1.
Demographic and clinical characteristics of the study groups
| SZ group (n=24) |
HC group (n=25) |
||||
|---|---|---|---|---|---|
| Variable | Mean (SD) | Mean (SD) | dfa | t test | p |
| Age, mean (SD) [range], years | 44.4 (9.7) [22–55] |
40.4 (11.4) [21–55] |
47 | 1.31 | 0.20 |
| Sex, No. M/F | 24 / 0 | 25 / 0 | |||
| Handednessb | 0.71 (0.25) | 0.78 (0.18) | 45 | 1.10 | 0.28 |
| Socioeconomic Statusc | |||||
| Subject’s | 3.5 (1.1) | 2.5 (1.2) | 46 | 2.91 | 0.01* |
| Parental | 2.6 (1.2) | 2.7 (1.3) | 45 | 0.28 | 0.78 |
| WRAT-3: reading score | 97.6 (12.1) | 103.5 (11.6) | 43 | 1.68 | 0.10 |
| Symptom onset, years | 23.9 (5.9) | NA | |||
| Duration of illness, years | 20.5 (10.3) | NA | |||
| Antipsychotic medication dosage (mg/day)d | 346.9 (265.5) | NA | |||
|
Neuroleptics, No. of patients TYP/ATYP/Overlap/Non-medication |
2 / 17 / 2 / 3 | NA | |||
| Number with/without family history of first-degree relatives with psychosise | 3 / 17 | NA | |||
| SANS global score | 11.9 (7.0) | NA | (n = 23) | ||
| SAPS global score | 9.3 (4.1) | NA | (n = 23) |
Abbreviations: SZ, schizophrenia; HC, healthy control subject; WRAT-3, Wide Range Achievement Test-3; SANS, the Scale for the Assessment of Negative Symptoms; SAPS, the Scale for the Assessment of Positive Symptoms; NA, data not applicable; TYP/ATYP, typical/atypical antipsychotics